drugset
Drugs / Signal Switch Receptor Modified TIL
last change 8 days ago re-read 3 minutes ago

Signal Switch Receptor Modified TIL

Cell therapy

Developed for
female reproductive system neoplasm
Investigated by
Shanghai 10th People's Hospital · Shanghai Juncell Therapeutics

Trials 1

today NCT05098171 · Ph 0
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT05098171 Sep 2021 → Sep 2026 overdue female reproductive system neoplasm, immunotherapy induced hypophysitis Shanghai Juncell Therapeutics Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Signal Switch Receptor Modified TIL ClinicalTrials.gov intervention name — accepted as the source's own label NCT05098171 ↗
Modality Cell therapy “Autologous TILs from tumor resections or biopsies are first gene modified” NCT05098171 ↗
Route Intravenous “autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes” NCT05098171 ↗